CancerDrs

Brain Cancer clinical trials in Idaho

5 actively recruiting brain cancer trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Idaho:
  • Massive Bio SYNERGY-AI site — Boise, Idaho

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25